Rachel Lefferdink1, Stephanie M Rangel1, Emma Guttman-Yassky2, Amy S Paller3, Margot Chima4, Erin Ibler1, Ana B Pavel4,5, HeeJin Kim4, Benedict Wu1, Hajar Abu-Zayed1, Jianni Wu4, Kathryn Jackson6, Giselle Singer4, Keith A Choate7. 1. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Dermatology, The Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, USA. emma.guttman@mountsinai.org. 3. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. apaller@northwestern.edu. 4. Department of Dermatology, The Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Medical Center, New York, NY, USA. 5. Department of Biomedical Engineering, University of Mississippi, University, Oxford, MS, USA. 6. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7. Departments of Dermatology, Genetics, and Pathology, Yale University School of Medicine, New Haven, CT, USA.
Abstract
IMPORTANCE: Treatment of congenital ichthyoses primarily focuses on reversing skin scaling and is not pathogenesis based. Recent studies showed Th17 immune skewing, as in psoriasis, across the spectrum of ichthyosis, suggesting that targeting this pathway might broadly reduce disease severity. OBJECTIVE: To determine whether secukinumab, an IL-17A inhibitor, can improve ichthyosis across several congenital ichthyosis subtypes. DESIGN: Exploratory 16-week double-blind, randomized, placebo-controlled trial comparing secukinumab 300 mg every 4wks to placebo (1:1 randomization) in adults with the four major congenital ichthyosis subtypes (NCT03041038), followed by a 16-week open-label phase to evaluate response of the placebo-first group and a 20-week extension for safety. Significant differences in secukinumab- vs. placebo-treated subjects at Wk16 in the Ichthyosis Area Severity Index (IASI) score and lack of increased mucocutaneous bacterial and/or fungal infections were the co-primary efficacy and safety endpoints, respectively. SETTING: Two tertiary referral centers: Northwestern University Feinberg School of Medicine, Chicago, and Mount Sinai Icahn School of Medicine, New York. PARTICIPANTS: Twenty subjects ≥ 18 yo with genotype-confirmed epidermolytic ichthyosis, Netherton syndrome, lamellar ichthyosis, or congenital ichthyosiform erythroderma with at least moderate erythroderma. RESULTS: IL-17A inhibition did not significantly reduce severity or increase mucocutaneous infections among the 18 who completed the 16-week double-blind phase. Five patients with 29-50% clinical improvement at Wk32 requested drug continuation. Th17-related biomarkers were not significantly reduced vs. baseline or placebo-treated levels. LIMITATIONS: Small sample size; heterogeneous ichthyosis subsets. CONCLUSION: IL-17 inhibition with secukinumab is safe, but not efficacious across the spectrum of adult ichthyoses. CLINICALTRIALS. GOV REGISTRATION NUMBER: NCT03041038; first posted on 02/02/2017.
IMPORTANCE: Treatment of congenital ichthyoses primarily focuses on reversing skin scaling and is not pathogenesis based. Recent studies showed Th17 immune skewing, as in psoriasis, across the spectrum of ichthyosis, suggesting that targeting this pathway might broadly reduce disease severity. OBJECTIVE: To determine whether secukinumab, an IL-17A inhibitor, can improve ichthyosis across several congenital ichthyosis subtypes. DESIGN: Exploratory 16-week double-blind, randomized, placebo-controlled trial comparing secukinumab 300 mg every 4wks to placebo (1:1 randomization) in adults with the four major congenital ichthyosis subtypes (NCT03041038), followed by a 16-week open-label phase to evaluate response of the placebo-first group and a 20-week extension for safety. Significant differences in secukinumab- vs. placebo-treated subjects at Wk16 in the Ichthyosis Area Severity Index (IASI) score and lack of increased mucocutaneous bacterial and/or fungal infections were the co-primary efficacy and safety endpoints, respectively. SETTING: Two tertiary referral centers: Northwestern University Feinberg School of Medicine, Chicago, and Mount Sinai Icahn School of Medicine, New York. PARTICIPANTS: Twenty subjects ≥ 18 yo with genotype-confirmed epidermolytic ichthyosis, Netherton syndrome, lamellar ichthyosis, or congenital ichthyosiform erythroderma with at least moderate erythroderma. RESULTS: IL-17A inhibition did not significantly reduce severity or increase mucocutaneous infections among the 18 who completed the 16-week double-blind phase. Five patients with 29-50% clinical improvement at Wk32 requested drug continuation. Th17-related biomarkers were not significantly reduced vs. baseline or placebo-treated levels. LIMITATIONS: Small sample size; heterogeneous ichthyosis subsets. CONCLUSION: IL-17 inhibition with secukinumab is safe, but not efficacious across the spectrum of adult ichthyoses. CLINICALTRIALS. GOV REGISTRATION NUMBER: NCT03041038; first posted on 02/02/2017.
Authors: Nareh V Marukian; Yanhong Deng; Geliang Gan; Ivy Ren; Wisblaude Thermidor; Brittany G Craiglow; Leonard M Milstone; Keith A Choate Journal: J Invest Dermatol Date: 2017-06-06 Impact factor: 8.551
Authors: C Bodemer; E Bourrat; J Mazereeuw-Hautier; F Boralevi; S Barbarot; D Bessis; C Blanchet-Bardon; E Bourdon-Lanoy; J-F Stalder; V Ribet; D Guerrero; V Sibaud Journal: Br J Dermatol Date: 2011-11 Impact factor: 9.302
Authors: James G Krueger; Keith A Wharton; Thomas Schlitt; Maria Suprun; Rebecca I Torene; Xiaoyu Jiang; Claire Q Wang; Judilyn Fuentes-Duculan; Nicole Hartmann; Thomas Peters; Irina Koroleva; Rainer Hillenbrand; Martin Letzkus; Xiaojing Yu; Yue Li; Anton Glueck; Anke Hasselberg; Brian Flannery; Mayte Suárez-Fariñas; Wolfgang Hueber Journal: J Allergy Clin Immunol Date: 2019-05-24 Impact factor: 10.793
Authors: Taylor R Erickson; Morgan B Murphrey; Hajar Abu-Zayed; Benedict Wu; Erin Ibler; Stephanie M Rangel; Amy S Paller Journal: Pediatr Dermatol Date: 2020-06-08 Impact factor: 1.588
Authors: Tali Czarnowicki; Helen He; Alexandra Leonard; Kunal Malik; Shai Magidi; Stephanie Rangel; Krishna Patel; Kara Ramsey; Morgan Murphrey; Teresa Song; Yeriel Estrada; Hue-Chi Wen; James G Krueger; Emma Guttman-Yassky; Amy S Paller Journal: J Invest Dermatol Date: 2018-04-14 Impact factor: 8.551
Authors: Diamant Thaçi; Andrew Blauvelt; Kristian Reich; Tsen-Fang Tsai; Francisco Vanaclocha; Külli Kingo; Michael Ziv; Andreas Pinter; Sophie Hugot; Ruquan You; Marina Milutinovic Journal: J Am Acad Dermatol Date: 2015-06-17 Impact factor: 11.527